We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
- Authors
Samineni, Divya; Venkatakrishnan, Karthik; Othman, Ahmed A.; Pithavala, Yazdi K.; Poondru, Srinivasu; Patel, Chirag; Vaddady, Pavan; Ankrom, Wendy; Ramanujan, Saroja; Budha, Nageshwar; Wu, Michael; Haddish‐Berhane, Nahor; Fritsch, Holger; Hussain, Azher; Kanodia, Jitendra; Li, Meng; Li, Mengyao; Melhem, Murad; Parikh, Apurvasena; Upreti, Vijay V.
- Abstract
The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced by the U.S. Food and Drug Administration, stands as a groundbreaking endeavor to reform dose selection of oncology drugs, presenting both opportunities and challenges for the field. To address complex dose optimization challenges, an Oncology Dose Optimization IQ Working Group was created to characterize current practices, provide recommendations for improvement, develop a clinical toolkit, and engage Health Authorities. Historically, dose selection for cytotoxic chemotherapeutics has focused on the maximum tolerated dose, a paradigm that is less relevant for targeted therapies and new treatment modalities. A survey conducted by this group gathered insights from member companies regarding industry practices in oncology dose optimization. Given oncology drug development is a complex effort with multidimensional optimization and high failure rates due to lack of clinically relevant efficacy, this Working Group advocates for a case‐by‐case approach to inform the timing, specific quantitative targets, and strategies for dose optimization, depending on factors such as disease characteristics, patient population, mechanism of action, including associated resistance mechanisms, and therapeutic index. This white paper highlights the evolving nature of oncology dose optimization, the impact of Project Optimus, and the need for a tailored and evidence‐based approach to optimize oncology drug dosing regimens effectively.
- Subjects
ANTINEOPLASTIC agents; DRUG development; CONSORTIA; QUALITY of life; CANCER patients
- Publication
Clinical Pharmacology & Therapeutics, 2024, Vol 116, Issue 3, p531
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.3298